Literature DB >> 2766459

Inactivation of O6-alkylguanine-DNA alkyltransferase in HeLa cells by cisplatin.

L G Wang1, R B Setlow.   

Abstract

Inactivation of O6-alkylguanine-DNA alkyltransferase (O6-AGT) in HeLa CCL2 cells by cisplatin was studied. HeLa CCL2 cells treated with cisplatin showed a dose-dependent decline in O6-AGT activity. After cisplatin was removed and replaced with fresh medium, the transferase level began to rise slowly. By 72 h slightly more than 80% of the activity was recovered. It seems that the activity of the alkyltransferase can be inactivated by platinated DNA adducts. The data suggest that the O6-platinum-guanine formation and the O6-alkyltransferase depletion are not responsible for cytotoxicity but may result in a base substitution mutation in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2766459     DOI: 10.1093/carcin/10.9.1681

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

1.  Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.

Authors:  Christos Christodoulou; Dimitrios Bafaloukos; Helen Linardou; Gerassimos Aravantinos; Aristotelis Bamias; Maria Carina; George Klouvas; Dimosthenis Skarlos
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

2.  Inhibition of O6-alkylguanine-DNA alkyltransferase and DNase I activities in vitro by some alkylating substances and antineoplastic agents.

Authors:  A Link; K Tempel
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).

Authors:  Carmen Balaña; Antonio López-Pousa; Alfonso Berrocal; Ricardo Yaya-Tur; Ana Herrero; Jose-Luis García; Javier Martín-Broto; Manuel Benavides; Miguel Cerdá-Nicolás; Rosa Ballester; Josep Balart; Jaume Capellades
Journal:  J Neurooncol       Date:  2004-12       Impact factor: 4.130

4.  Rapid gene-specific repair of cisplatin lesions at the human DUG/DHFR locus comprising the divergent upstream gene and dihydrofolate reductase gene during early G1 phase of the cell cycle assayed by using the exonucleolytic activity of T4 DNA polymerase.

Authors:  N J Rampino; V A Bohr
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

5.  Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.

Authors:  B Geoerger; G Vassal; F Doz; J O'Quigley; M Wartelle; A J Watson; M-A Raquin; D Frappaz; P Chastagner; J-C Gentet; H Rubie; D Couanet; A Geoffray; L Djafari; G P Margison; F Pein
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

6.  Liquid biopsies in patients with diffuse glioma.

Authors:  Myron G Best; Nik Sol; Sebastiaan Zijl; Jaap C Reijneveld; Pieter Wesseling; Thomas Wurdinger
Journal:  Acta Neuropathol       Date:  2015-02-27       Impact factor: 17.088

7.  O6-methylguanine-DNA methyltransferase modulates cisplatin-induced DNA double-strand breaks by targeting the homologous recombination pathway in nasopharyngeal carcinoma.

Authors:  Shang-Hung Chen; Wen-Tsung Huang; Wan-Chen Kao; Sheng-Yen Hsiao; Hsin-Yi Pan; Chin-Wen Fang; Yow-Ling Shiue; Chia-Lin Chou; Chien-Feng Li
Journal:  J Biomed Sci       Date:  2021-01-04       Impact factor: 8.410

8.  Platinum-based chemotherapy in recurrent high-grade glioma patients: retrospective study.

Authors:  Ermir Roci; Bujar Cakani; Gramoz Brace; Teona Bushati; Arben Rroji; Mentor Petrela; Gentian Kaloshi
Journal:  Med Arch       Date:  2014
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.